MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-21-2026
China SXT Pharmaceuticals Cash and Cash Equivalents 2011-2026 | SXTC
Annual Cash and Cash Equivalents China SXT Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 13.4 M | 7.29 M | 9.13 M | 658 K | 65.6 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.4 M | 65.6 K | 6.1 M |
Quarterly Cash and Cash Equivalents China SXT Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 15.5 M | - | 31.3 K | - | 13.3 M | - | 10.4 M | - | 7.29 M | - | 8.25 M | - | 9.29 M | - | 384 K | - | 658 K | - | - | - | 65.6 K | - | - | - | 11.4 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15.5 M | 11.4 K | 5.93 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Regeneron Pharmaceuticals
REGN
|
3.12 B | $ 742.1 | -1.93 % | $ 77.6 B |  USA |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
AbbVie
ABBV
|
5.23 B | $ 211.9 | 0.37 % | $ 375 B | USA |
 |
Replimune Group
REPL
|
111 M | $ 7.26 | -3.71 % | $ 585 M | USA |
 |
AbCellera Biologics
ABCL
|
129 M | $ 3.28 | -2.24 % | $ 980 M |  Canada |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
4.08 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | France |
 |
Rigel Pharmaceuticals
RIGL
|
40.6 M | $ 26.28 | -0.34 % | $ 473 M | USA |
 |
Aileron Therapeutics
ALRN
|
3.22 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arena Pharmaceuticals
ARNA
|
220 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.59 M | - | -52.27 % | $ 4.45 M | USA |
 |
Avidity Biosciences
RNA
|
383 M | $ 13.07 | -0.23 % | $ 1.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
222 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | Canada |
 |
Rhythm Pharmaceuticals
RYTM
|
54.3 M | $ 77.56 | -5.31 % | $ 5.04 B | USA |
 |
Avid Bioservices
CDMO
|
38.1 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
70.5 M | $ 12.27 | -12.11 % | $ 1.86 B | USA |
 |
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
SIGA Technologies
SIGA
|
155 M | $ 5.36 | 7.96 % | $ 383 M | USA |
 |
Silence Therapeutics plc
SLN
|
54 M | $ 4.92 | -7.34 % | $ 622 M | Britain |
 |
SELLAS Life Sciences Group
SLS
|
71.8 M | $ 4.47 | -9.69 % | $ 487 M | USA |
 |
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
51.8 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
50 M | - | - | $ 3.74 B | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
5.67 M | $ 1.08 | -1.38 % | $ 22.2 M | Israel |
 |
Enochian Biosciences
ENOB
|
92.7 K | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Summit Therapeutics
SMMT
|
225 M | $ 16.59 | -3.88 % | $ 12.4 B | Britain |
 |
Spruce Biosciences
SPRB
|
48.9 M | $ 62.07 | -10.19 % | $ 47.6 M | USA |